Holmusk logo

Holmusk

Behavioral health data analytics platform for real-world evidence and clinical decision support

Data & Analytics Growth Series A/B/C+, PE-Backed
Visit Website

Overview

Holmusk is a behavioral health data analytics company that provides real-world evidence solutions for the mental health sector. Its platform serves pharmaceutical companies, health systems, payers, and research institutions seeking clinical insights for drug development, care pathway design, and regulatory submissions.

The company operates the NeuroBlu platform, which combines a large de-identified patient database with a no-code analytics layer. NeuroBlu aggregates longitudinal clinical records from health system partners across the United States, covering conditions such as major depressive disorder, substance use disorders, generalized anxiety disorder, ADHD, and PTSD. A separate clinical decision support tool, MaST, is deployed within UK community mental health settings.

Holmusk has raised over USD 109 million through multiple rounds. A Series B of USD 45 million in January 2023 was led by Veradigm, with continued participation from Optum Ventures, Health Catalyst Capital, Northwell, and dRx Capital. A partnership announced in June 2025 with Iris Telehealth expanded the company's reach into telehealth-enabled behavioral health care delivery.

Products & Services

NeuroBlu Data

A de-identified longitudinal patient database covering 41+ million records across 50 U.S. states, spanning 20+ years of clinical history. Condition coverage includes major depressive disorder (11.7M+ patients), substance use disorders (9.9M+), generalized anxiety disorder (6.5M+), ADHD (5.1M+), and PTSD (2.2M+).

Key Features

  • De-identified, research-grade longitudinal data
  • Broad geographic coverage across all 50 U.S. states
  • Multi-condition mental health coverage with deep patient histories

Target Users: Pharma and biotech researchers, payers, health economists, academic institutions

NeuroBlu Analytics

A no-code analytics platform built on top of the NeuroBlu dataset, enabling clinical and commercial teams to design and execute behavioral health studies without requiring specialized data science expertise.

Key Features

  • Pre-designed study templates for common research designs
  • No-code interface with enterprise SSO integration
  • Supports cohort analysis, outcomes research, and regulatory evidence generation

Target Users: Clinical researchers, health economics teams, medical affairs departments

Custom Analytics Services

Collaborative research engagements where Holmusk's clinical and data science teams design and execute studies on behalf of clients. Applicable to complex or novel research questions requiring tailored methodology.

Target Users: Pharmaceutical companies, payers, academic medical centers

MaST (Management and Supervision Tool)

A clinical decision support tool deployed in UK community mental health settings. MaST applies predictive analytics to support clinician caseload management and early identification of patients at elevated risk.

Key Features

  • Predictive risk scoring for community mental health caseloads
  • Decision support for clinicians managing patient populations
  • Deployed in UK NHS-affiliated settings

Target Users: Mental health clinicians and community care teams in the UK

At a Glance

Founded
2015
Headquarters
New York, New York (offices in Singapore, London, Basel)
Employees
51-200
Funding
Series A/B/C+, PE-Backed

Category & Focus

Category
Data & Analytics
Subcategories
Real-World Evidence Clinical Decision Support Health Data Platform
Insurance Verticals
Health
Target Customers
Carriers, Employers

Customers

  • Iris Telehealth (partnership announced June 2025)
  • UK NHS-affiliated mental health providers (MaST deployment)

Links

Similar Companies

Last updated: 2026-05-12